Myrelez (Lanreotide Acetate)

Lanreotide acetate, the active ingredient in Myrelez, is a somatostatin analog presented as a sterile solution for subcutaneous injection. It treats acromegaly and neuroendocrine tumors in adult patients. GNH USA supplies Myrelez as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Myrelez is a somatostatin analog used to control hormone‑driven disorders within the endocrine and neuroendocrine disease families.

Acromegaly: reduces excess growth hormone and IGF‑1 levels, helping to control disease activity. Neuroendocrine tumors (functional): controls hormone‑related symptoms and can slow tumor progression. Carcinoid syndrome: alleviates flushing, diarrhea and other secretory symptoms associated with serotonin‑secreting tumors.

Adverse reactions may occur with lanreotide acetate therapy.

Common Side Effects: - Injection site pain or erythema - Abdominal discomfort or cramps - Diarrhoea - Nausea - Headache - Mild hyperglycaemia

Serious or Rare Side Effects: - Gallbladder disease (cholelithiasis, cholecystitis) - Acute pancreatitis - Severe hyperglycaemia or new‑onset diabetes mellitus - Anaphylactic or severe hypersensitivity reactions - Cardiac arrhythmias - Pituitary apoplexy (rare)

Before initiating therapy, clinicians should consider several safety measures.

Monitor glucose: assess blood‑sugar levels regularly, especially in diabetic patients. Assess gallbladder: evaluate for gallstones or biliary disease prior to treatment. Check for hypersensitivity: discontinue if signs of allergic reaction appear. Dose adjustment: consider renal or hepatic impairment when determining dose. Pregnancy and lactation: use only if benefit outweighs potential risk. Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Lanreotide acetate can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Concomitant cyclosporine: may increase lanreotide exposure. - Octreotide co‑administration: additive somatostatin effects can exacerbate gastrointestinal symptoms. - Antidiabetic agents: risk of severe hyperglycaemia.

Moderate Interactions (Monitor Closely): - Oral contraceptives: possible reduction in hormonal efficacy. - CYP450 substrates: monitor for altered metabolism of co‑administered drugs. - Antiplatelet or anticoagulant therapy: increased bleeding tendency may occur.